



BIODIEM LTD  
ABN 20 096 845 993  
Level 4,  
100 Albert Road,  
South Melbourne, Victoria, 3205  
Australia  
Phone: +613 9692 7240  
Web: [www.biodiem.com](http://www.biodiem.com)

## Announcement

### Company Update and EOFY 2018 Information

**Melbourne, 2 August 2018:** Infectious disease therapy and vaccine development company BioDiem Ltd and its subsidiary company Opal Biosciences Ltd (“Opal”) are pleased to provide the following information.

#### Live attenuated flu virus (LAIV) vaccine licensee progress in China

BioDiem’s LAIV licensee in China, Changchun BCHT Biotechnology Co, has advised that it has submitted an application for marketing approval of its LAIV vaccine to the Chinese FDA. The timeline for regulatory approval is uncertain. China is the second largest pharmaceutical market in the world estimated at US\$122.6 billion in 2017<sup>1</sup>. Although up until 2014, vaccination coverage for influenza in China was less than 2%, more recently there is support for wider coverage. China has the largest population of older adults in the world, with 201.3 million older than 60 years in 2014<sup>2</sup>.

#### Opal Biosciences fund-raising launch

Opal seeks to raise \$1.5m by the issue of 6m fully paid ordinary shares to continue development of BDM-I as an injectable (Opal-I) product candidate; and a topical (Opal-T) product candidate.

Opal reserves the right to accept over-subscriptions for up to a further 4m shares at an issue price of \$0.25 per share to raise up to a further \$1m. Opal will also issue 1 option for every 1 share subscribed (including over-subscriptions), to applicants whose valid application forms together with all application money are received on or prior to 2 October 2018 and prior to the offer closing. The maximum number of options Opal will issue assuming the maximum over-subscription amount is also achieved is 10m. The option exercise price is \$0.25 and the option expiry date is 2 October 2019.

#### EOFY Share Price information

For EOFY 2018 valuation purposes, the last sale price of

- BioDiem ordinary shares = \$0.08
- BioDiem preference shares = \$0.08

For those BioDiem shareholders who also separately hold shares in Opal, the EOFY 2018 valuation of Opal Biosciences ordinary shares = \$0.20.

#### Shareholder Information at Share Registry, Computershare.

Shareholders are asked to ensure their contact details/ email addresses are up-to-date at Computershare. This can be done online via the Computershare Investor Centre ([www.computershare.com.au](http://www.computershare.com.au)).

- ENDS -

#### About BioDiem Ltd ([www.biodiem.com](http://www.biodiem.com))

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. BioDiem’s business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

<sup>1</sup> 2018 and Beyond: Outlook and Turning Points, IQVIA™ Institute for Human Data Science, March 2018.

<sup>2</sup> Phillips & Feng, *Challenges for the Aging family in the People’s Republic of China*, *Can J Aging* 2015; 34 (3): 290-304.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is marketed in India. BioDiem's antimicrobial technology, BDM-I, is being developed through its subsidiary, Opal Biosciences Ltd. For additional information, please visit [www.biodiem.com](http://www.biodiem.com).

**About Opal Biosciences Ltd ([www.opalbiosciences.com](http://www.opalbiosciences.com))**

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more widespread and common difficult-to-treat infections, and the paucity of upcoming new treatments. This need has spurred the EU and US to introduce significant financial incentives to encourage development of new anti-infectives. Opal is currently seeking funding to support the next stage of development of its products: Opal-I, an injectable product, and Opal-T, which can be applied to the skin. For additional information, please visit [www.opalbiosciences.com](http://www.opalbiosciences.com).

**Further information**

Julie Phillips, Chief Executive Officer, BioDiem Ltd

Phone +61 3 9692 7222

Email [jphillips@biodiem.com](mailto:jphillips@biodiem.com)

Twitter @biodiem @opalbiosciences